ACT Brief: Phase I Back-Office Automation Priorities, Early Phase Data Interpretation Under Capital Pressure, and Syneos AI Ecosystem Expansion

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part two of her interview, Amber Hill, PhD, founder and CEO of Research Grid, identified the administrative back-office processes causing the most friction in Phase I trials. Purpose-built, traceable AI models designed for regulatory environments are the right tool for addressing them, with the biggest early wins in scheduling, protocol compliance monitoring, and data reconciliation.
• In a new contributed article, Deborah Phippard, PhD, chief scientific officer of Precision for Medicine, addressed how sponsors can build lean but robust early-phase evidence packages when investors demand patient-level data as it emerges. Without biological context, two responders and two nonresponders do not establish a trend, and biobanked samples retained prospectively allow teams to investigate outliers or rescue ambiguous datasets at modest incremental cost.
• Syneos Health announced three AI platform partnerships expanding its clinical development capabilities, including integrations with Causaly for evidence-based protocol strategy, Databricks for near-real-time operational data reducing source-to-insight time from days to hours, and Microsoft for workflow automation. Together, the partnerships are designed to create a unified intelligence environment connecting operational, clinical, and real-world data across the development lifecycle.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.